Triumeq - Treatment Option for HIV-1 Infection in All Age Groups

Triumeq is a prescription medication used to manage HIV-1 infection in adults and children. It combines three different drugs in a single tablet.
Category
Drug
Where to get
Available with a prescription from pharmacies or healthcare providers
Applicable for
Prepared by Shruti Sahoo, reviewed by Dr. Eugene Smith

Triumeq FAQ


Image credit: medscape.com

How does Triumeq work?

1. How it works Triumeq is a fixed-dose combination tablet that contains three antivirals: abacavir, dolutegravir, and lamivudine, which may be used to treat human immunodeficiency virus type 1 (HIV-1) infection in adults and children weighing at least 10 kg (22 pounds). Each component of Triumeq works differently.

Is Triumeq a prescription drug?

Triumeq and Triumeq PD are prescription medicines approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and children. Triumeq is approved for use in adults and children who weigh at least 55 lb (25 kg). Triumeq PD is approved for use in children who weigh 22 lb (10 kg) to less than 55 lb (25 kg).

What information can I find about Triumeq?

Please refer to our terms and conditions. On this page about Triumeq you will find information relating to side effects, age restrictions, food interactions, whether the medicine is available at a government subsidised price on the pharmaceutical benefits scheme (PBS) as well as other useful information.

Who should use Triumeq?

package leaflet (annex IIIB). Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with HIV without documented or clinically suspected resistance to any of the three antiretroviral agents in Triumeq.

What is Triumeq?

TRIUMEQ is a pill and contains abacavir, dolutegravir, and lamivudine. TRIUMEQ is also available as tablets for oral suspension: TRIUMEQ PD. View the Patient Information with Important Warnings. Learn more about TRIUMEQ (abacavir, dolutegravir, and lamivudine). See Full Safety and Prescribing Info, including Boxed Warning.

Is Triumeq a single-component medicine?

All three active substances in Triumeq are already available in the EU as single-component medicines: abacavir has been authorised as Ziagen since 1999, lamivudine as Epivir since 1996, and dolutegravir as Tivicay since 2014. The combination of abacavir and lamivudine has been authorised as Kivexa since 2004.

Does Triumeq work for HIV?

HIV is a virus that attacks your immune system, which is your body’s defense against infection. Another version of Triumeq, called Triumeq PD, is available to treat HIV in children who weigh from 10 kg (about 22 lb) to less than 25 kg (about 55 lb). Triumeq and Triumeq PD have certain limitations of use.

Who can use Triumeq PD?

For this purpose, Triumeq is approved for use in adults as well as children who weigh 25 kilograms (kg) or more (about 55 pounds [lb] or more). Triumeq PD is approved for use in children who weigh from 10 kg (about 22 lb) to less than 25 kg (about 55 lb).

Triumeq References

If you want to know more about Triumeq, consider exploring links below:

Explore Related Topics

What collaborative efforts are needed to address antiviral resistance in HIV care?

Explore the importance of collaborative initiatives in addressing antiviral resistance in HIV care. Discuss the roles of healthcare providers, researchers, policymakers, and community organizations in developing comprehensive strategies to combat resistance challenges. Share your ideas on fostering collaboration to enhance HIV management outcomes.

What are some key considerations when switching antiviral medications for HIV treatment?

Share insights on the factors to be mindful of when transitioning between different antiviral medications during HIV treatment and potential challenges that may arise.

How can healthcare providers adapt to antiviral resistance trends in HIV?

Exchange ideas and strategies on how healthcare providers can adapt to evolving antiviral resistance trends in HIV management. Share practical tips, resources, and collaborative approaches to enhance patient care and clinical outcomes in the face of resistance challenges.

What is the role of antiviral agents in HIV prevention strategies?

Explore the role of antiviral agents in HIV prevention strategies, including pre-exposure prophylaxis (PrEP) and their effectiveness in reducing HIV transmission.